3358 Auer, Rebecca Bcl-2 Antisense (Genasensetm) Induces Apoptosis and Potentiates Activity of Both
Cytotoxic Chemotherapy and Rituximab in Primary CLL Cells.3542 Bacigalupo, Andrea A Predictive Score for Transplant Related
Mortality (TRM) Following Allogeneic Stem Cell Transplantation: Day +7 Serum Cholinesterase, Total Protein, Blood Urea Nitrogen, Gamma Glutamyl Transferase, Donor Type and Cells Dose.3359 Bannerji, Rajat Campath-1H Antibody Induces Transmembrane Signaling In Vitro and In Vivo
in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance in Part through Caspase Mediated Apoptosis.1973 Battle, Traci Activation of the STAT Signaling pathway Is Required for CLL Differentiation in Response to Bryostatin 1.
1939 Bentz, Martin Clinical Relevance of Genomic Aberrations in Diffuse Large B-Cell Lymphoma - An Analysis within a Multicentric Treatment Trial of the
German High Grade Lymphoma Study Group3075 Bolwell, Brian Rituximab Does Not Reduce CD34+ Cell Yield
in Patients Mobilized with Etoposide Plus GCSF .3017 Bosga-Bouwer, Anneke Follicular Lymphoma Grade IIIB Includes
Three Cytogenetically Defined Subgroups with Primary t(14;18), 3q27 or Other Translocations; t(14;18) and 3q27 Are Mutually Exclusive .3579 Bosly, A. Interferon alphasub2/subb Does Not
Prolong Response after Intensive Therapy and Autologous Stem Cell Transplantation for Relapsing Lymphoma. An International Randomized Study on 221 Patients.2011 Bredeson, Christopher Salvage Therapy for CLL: HLA-Identical
Sibling Transplantation vs. Non-Transplant Therapies: An International Bone Marrow Transplant Registry and MD Anderson Cancer Center (MDACC) Study.3074 Brown, Randy Mobilization of Allogeneic PBSC with GM-CSF
Instead of G-CSF Is Associated with a Reduced Risk of Acute Graft-Vs-Host Disease (GVHD). (Note from Greg - I am not sure about the difference between GM-CSF vs G-CSF, iIwasn't aware there was a difference)3212 Byrd, John Concurrent Rituximab and Fludarabine Has a
Higher Complete Response Rate Than Sequential Treatment in Untreated Chronic Lymphocytic Leukemia (CLL) Patients:3097 Carella, A.M. Autografting Followed by Nonmyeloablative
Allografting for Advanced Lymphoma: A style='font-size: 10.0pt; Higher Than Expected Remission Rate and3214 Cazin, B. Oral Fludarabine and Cyclophosphamide in
Previously Untreated CLL: Preliminary Data on3166 Chen, Weiyi Gene Amplification in Diffuse Large B-Cell Lymphoma (DLBCL) Detected by Array-Based
Screening Predicts Clinical Outcome.3025 Coiffier, Bertrand Rituximab Plus CHOP (R-CHOP) in theTreatment of Elderly Patients with Diffuse Large B-Cell Lymphoma. An Update of the
GELA Study.3586 Coiffier, Bertrand Cost-Effectiveness of Rituximab in Treatment of Diffuse Large B-Cell Lymphoma .
3573 Colombat, Philippe Value of Autologous Stem Cell Transplantation in First Line Therapy of Follicular Lymphoma
with High Tumor Burden: First Results of the Randomized GOELAMS 064 Trial.3354 Conconi, Annarita Activity of Rituximab in Extranodal Marginal
Zone Lymphomas (MALT-Type).3355 Connors, Joseph Flavopiridol for Mantle Cell Lymphoma:
Moderate Activity and Frequent Disease Stabilization.3503 Davis, Thomas Results of a Randomized Study of Bexxartm
(Tositumomab and Iodine I 131 Tositumomab) vs. Unlabeled Tositumomab in Patients with Relapsed or Refractory Low-Grade or Transformed Non-Hodgkinssquotes Lymphoma (NHL).3347 Emile, Jean-Francois Prognostic Significance of the Detection of
Epstein Barr Virus-Infected Cells in Nodal Peripheral T-Cell Lymphomas, Unspecified. A GELA Study of 147 Patients .2013 Esteve, J. Stem Cell Transplantation (SCT) for Chronic
Lymphocytic Leukemia (CLL): Outcome and Prognostic Factors after Autologous and Allogeneic Transplants.3550 Feinstein, Lyle Nonmyeloablative Allogenic Transplantation as
a Treatment for Relapsed Hematologic Malignancy after a Failed Conventional Autologous or Allogeneic Transplant.3501 Hagenbeek, A. Fludarabine Compared with CVP
Chemotherapy in Newly Diagnosed Patients with Stages III and IV Low Grade Malignant Non-Hodgkinscquotes Lymphoma. Final Analysis of a Prospective Randomized Phase III Intergroup Study in 381 Patients.3507 Hiddemann, Wolfgang The Addition of Rituximab to Combination
Chemotherapy with Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) Results in a Significant Increase of Overall Response as Compared to FCM alone in Patients with Relapsed or Refractory Follicular (FCL) and Mantel Cell Lymphomas (MCL) -- Results of a Prospective Randomized Comparison of the German Low Grade Study Group (GLSG) .3572 Hiddemann,Wolfgang Myeloablative Radiochemotherapy Followed by Autologous Blood Stem Cell
Transplantation Leads to a Significant Prolongation of the Event-Free Survival in Patients with Mantel Cell Lymphoma (MCL) -- Results of a Prospective Randomized European Intergroup Study.3578 Horwitz, Steven Phase II Trial of Rituximab as Adjuvant
Therapy to High Dose Chemotherapy and Peripheral Blood Stem Cell Transplantation for Relapsed and Refractory Aggressive Non- Hodgkinssquotes Lymphomas .3018 Jardin, Fabrice Follicular Lymphoma (FL) with BCL6
Rearrangement: A Lymphoma Subtype with Distinct Pathological, Molecular and Clinical Characteristics.3019 Jardin, Fabrice BCL6 Gene Expression Is Related to the
Lymphoma Subtype: A Real Time Quantitative PCR (Q RT-PCR) Study.3505 Leonard, John Triple Modality Therapy for Follicular Low-
Grade Lymphoma: Initial Treatment with Fludarabine Followed by Bexxartm (Tositumomab and Iodine I 131 Tositumomab).3506 Leonard, John Combination Monoclonal Antibody Therapy for Lymphoma: Treatment with Epratuzumab (Anti-
CD22) and Rituximab (Anti-CD20) Is Well Tolerated .3215 Lundin, J. Phase II Study of Subcutaneous Alemtuzumab (Campath-1H) Therapy of Patients with
Previously Untreated Chronic Lymphocytic Leukemia (CLL).3502 Maloney, David A Phase II Trial of CHOP Followed by
Rituximab Chimeric Monoclonal Anti-CD20 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkindsquotes Lymphoma :1949 McCormick, Alison Individualized Human scFv Vaccines
Produced in Plants for the Treatment of Non- Hodgkinssquotes Lymphoma: Anti-Idiotype Responses in Vaccinated Mice Confirm Relevance to the Tumor Ig.3568 Michallet, Mauricette Analysis of Prognostic Factors on the
Outcome of Autologous and Allogeneic Stem Cell Transplantations (SCT) for Chronic Lymphocytic Leukemia (CLL).3024 Miller, T.P. CHOP Alone Compared to CHOP Plus
Radiotherapy for Early Stage Aggressive Non- Hodgkinssquotes Lymphomas: Update of the Southwest Oncology Group (SWOG)3213 OBrien,Susan Bcl-2 Antisense (Genasense) as Monotherpay
for Refractory Chronic Lymphocytic Leukemia.3026 Pfreundschuh, Michael CHOEP (Chop + Etoposide): The New
Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non- Hodgkinssquotes Lymphoma (NHL).3027 Pfreundschuh, Michael 2-Weekly Chop (CHOP-14): The New
Standard Regimen for Patients with Aggressive Non-Hodgkinssquotes Lymphoma (NHL) gt60 Years of Age .3504 Press, Oliver A Phase II Trial of CHOP Followed by
Bexxartm (Tositumomab and Iodine-131- Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas (SWOG 9911).3030 Romaguera, Jorge Mantle Cell Lymphoma (MCL) - High Rates of
Complete Remission (CR) and Prolonged Failure-Free Survival (FFS) with Rituxan- HyperCVAD (R-HCVAD) without Stem Cell Transplant (SCT).3576 Santini, Gino Vacop-B vs Vacop-B + High-Dose Sequential Therapy (HDS) for Aggressive Non-Hodgkin's
Lymphoma (NHL).3029 Spaepen, Karoline Early Restaging Positron Emmision
Tomography (PET) with 18FFluorodeoxyglucose FDG)Predicts Outcome in Patients with Aggressive Non Hodgkin Lymphoma (NHL).1936 Sreenivasan, Gayatri Bcl-6 Gene Rearrangements Do Not Have
Prognostic Significance in Diffuse Large B Cell Lymphoma.3342 Thomas, Deborah Rituximab and Hyper-CVAD for Adult
Burkitts (BL) or Burkitts-Like (BLL) Leukemia or Lymphoma .1947 Weng, Wen-Kai Human Anti-CD40 Antagonistic Antibodies
Inhibit the Proliferation of Human B Cell Non- Hodgkins Lymphoma.3500 Zinzani, Pier A Randomized Trial of Fludarabine and
Mitoxantrone Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma.1737 Outcome of Non-Myeloablative Stem Cell Transplantation for NHL Is Dependent on Histology: Good for Patients with Low Grade Disease and Poor for Those with High Grade Lymphoma.
1440 A Phase 2 Study Demonstrating Recombinant Idiotype Vaccine Elicits Specific Anti-Idiotype Immune Responses in Aggressive Non-Hodgkin's Lymphoma.
2553 Continuous Infusion Endostatin Abrogates High-Grade Lymphoma Growth In Vivo, Possibly by Inhibition of Clonogenic Endothelial Progenitors.
1416 Incidence of Myelodysplastic Syndromes (tMDS) and Acute Myeloid Leukemia (tAML) in Patients with Low-Grade Non-Hodgkin's Lymphoma (LG-NHL) Treated with Bexxar™.
2566 style="mso-spacerun: yes"> Interleukin-12 (IL-12) Decreases Serum VEGF and b-FGF Levels and Induces Clinical Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL).
1423 The Effects of Methylprednisolone (MP) on the Biological Anti-Tumor Activity of Rituximab on Non-Hodgkin Lymphoma (NHL) Cell Lines.
2557 Retroviral Mediated Expression of Truncated, Soluable Vascular Endothelial Growth Factor Receptor-2 (tsFlk-1) Inhibits Growth of Human High-Grade Non-Hodgkin's Lymphoma In Vivo.
3506 Combination Monoclonal Antibody Therapy for Lymphoma: Treatment with Epratuzumab (Anti-CD22) and Rituximab (Anti-CD20) Is Well Tolerated.
4732 A Phase I/II Study of Rituxan and Interleukin 2 (IL-2) in Patients with Low Grade or Mantle Cell Non Hodgkins Lymphoma (NHL)- Preliminary Results.
2519 Progression Free Survival (PFS) after Six Years (Median) Follow-Up of the First Clinical Trial of Rituximab/CHOP Chemoimmunotherapy .
4712 Phase II Study of Thalidomide in Patients with Recurrent Hodgkin's Disease (HD)and Non-Hodgkin's Lymphomas (NHL).
4698 Rituxan Plus GM-CSF for the Treatment of Low Grade Follicular (B Cell) Non-Hodgkin's Lymphoma (NHL).
2537 Anti CD20 Antibody (Rituximab) Therapy Leads to High Molecular Remission Rate with Favourable Outcome in Patients with Non-Hodgkin's Lymphoma.
2550 Phase I Study To Assess Safety and Activity of Oligodeoxynucleotide CpG 7909 (Promune™) in Patients with Previously Treated Non-Hodgkin's Lymphoma.
1949 Individualized Human scFv Vaccines Produced in Plants for the Treatment of Non-Hodgkin's Lymphoma: Anti-Idiotype Responses in Vaccinated Mice Confirm Relevance to the Tumor Ig.
1950 A Clinical Trial of Sequential Dendritic Cell and Protein/Adjuvant Idiotype Vaccines in Patients with Follicular Lymphomas.
3503 Results of a Randomized Study of Bexxar™ (Tositumomab and Iodine I 131 Tositumomab) vs. Unlabeled Tositumomab in Patients with Relapsed or Refractory Low-Grade or Transformed Non-Hodgkin's Lymphoma (NHL).
1945 Anti-Tumor Activity of the Proteasome Inhibitor PS-341 in Mantle Cell Lymphoma B Cells.
5376 Autologous Transplantation as Primary Treatment Strategy Versus at Relapse for Follicular Lymphoma upon Long Term Follow-Up.
4710 Phase I Trial of Interleukin-2 (IL-2) and Rituximab in Patients (pts) with Relapsed or Refractory B-Cell Lymphomas (R/R-BCL).
2527 Bexxar™ (Tositumomab and Iodine I 131 Tositumomab) Results in Durable Long-Term Responses in Patients with Poor Prognosis, Multiple Relapsed (Rel), and Refractory (Ref) Low-Grade or Transformed Low-Grade Non-Hodgkins Lymphoma (NHL).
1415 Rituximab Treatment Results in Impaired Secondary Humoral Immune Responsiveness.
2531 Final Results of a Phase II Study To Evaluate the Efficacy and Safety of Treatment and Retreatment with Rituximab in Relapsed Follicular or Low-Grade NHL.
2522 Tumor-Specific Idiotype Vaccines in the Treatment of Low Grade B-Cell Lymphoma.
845 The Presence of a Caregiver Is a Powerful Prognostic Variable of Survival Following Allogeneic Bone Marrow Transplantation. 2523 Therapeutic Activity of Humanized Anti-CD20 Monoclonal Antibody and Polymorphism in IgG Fc Receptor FcgRIIIa Gene. 1811 Rituximab in Lymphoma: A Review of a Province-Wide Initiative after One Year.
1545 Induction of Apoptosis by IDEC-152 (Anti-CD23) in Lymphoma Cells.
541 Inter-Institutional Second Opinion Pathologic Review of Lymphoprofilerative Disorders after WHO Classification.
3502 A Phase II Trial of CHOP Followed by Rituximab Chimeric Monoclonal Anti-CD20 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin"s Lymphoma: SWOG 9800.
4916 Effectiveness of Mabthera in Advanced Stages B-CLL and for In Vivo Purging Autologous Peripheral Stem Cell Transplantation.
5307 Outcome of 21 Patients Undergoing Unrelated Bone Marrow Transplant for Hematologic Malignancies at a Single Institution.
4716 style="mso-spacerun: yes"> Radiolabeled Anti-Tenascin Antibody for Refractory Non-Hodgkins Lymphoma (NHL
774 Agura, Edward A Novel Non-TBI Conditioning Regimen in 27
Patients Undergoing Allogeneic Bone Marrow1424 Ahmed, Shahid Low-Grade B-Cell Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: A
Descriptive Natural History of a Rare Disease.1394 Akasaka, Takashi Analysis of BCL6 Gene Translocations in
Higher-Grade Transformation of Follicle Center Lymphomas (FCL).829 Albrecht, Federico Evaluation of Safety, Efficacy and
Pharmacokinetics of Administering Daily IV Busulfan (Busulfex) in Patients with Advanced Hematologic Malignancies Undergoing Stem Cell Transplant (SCT).1669 Alessandrino, Emilio Risk Factors for Extensive Chronic GvHD after
Allogeneic Stem Cell Transplantation: Definition of a Scoring System.842 Ali, Yousuf Ideal or Actual Body Weight To Calculate
CD34+ Cell Doses for Autologous Hematopoietic Stem Cell Transplantation?778 Alyea, Edwin Nonmyeloablative Conditioning with Low Dose Intravenous Busulfan and Fludarabine Is Safe
and Sufficient To Obtain Allogeneic Stem Cell Engraftment in Patients with Hematologic Malignancies.813 Anaissie, Elie Risk Factors for Infectious Morbidity and
Mortality in Patients with Hematological Malignancies Receiving Myeloablative Chemotherapy: The Importance of Mucositis.1765 Anderson, Daniel Allogeneic Related Donor Peripheral Blood vs. Bone Marrow Transplants: A Comparative
Analysis of Major Complications.2533 Ansell, Stephen Subsequent Chemotherapy Regimens Are
Well Tolerated after Radioimmunotherapy with Zevalintm for Non-Hodgkin Lymphoma.850 Arpinati, Mario Early Recovery of Dendritic Cells Type-2
(DC2) after Allogeneic PBSC Transplantation Correlates with Reduced GVHD.1738 Badros, Ashraf Improved Outcome of Allogeneic Transplants in High Risk Multiple Myeloma ((MM) Patients (pts) Following Non-Myeloablative
Conditioning.2512 Bairey, O. Expression of Basic Fibroblast Growth Factor Is Associated with Poor Outcome in Non-
Hodgkin's Lymphoma1686 Baker, K. New Malignancies Following Blood or Marrow
Stem Cell Transplantation: Incidence and Risk Factors.2823 Barker, Juliet Outcome of HLA-Matched Unrelated Donor
Bone Marrow Transplantation in Adults: A 10- Year Experience.779 Baron, Frederic Nonmyeloablative Stem Cell Transplantation (NMSCT) with CD8-Depleted or CD34-
Selected PBSC : A Pilot Study.1391 Barrans, Sharon Diffuse Large B Cell Lymphomas with a
t(14;18) Have an Inferior Outcome Compared to bcl2 Positive Cases Lacking the Translocation.791 Battiwalla, Minocher Do Adverse Cytokine Expression Profiles in Nonmyeloablative Stem Cell Transplant (NST)
Recipients Play a Lesser Role Than in Standard Transplantation?2776 Benekli, Mustafa Granulocyte-Macrophage Colony Stimulating
Factor (GM-CSF) Mobilized Donor Bone Marrow (BM) Stem Cells along with GM-CSF Administration Post Allogeneic Bone Marrow Transplantation (ABMT) To Reduce the Incidence of Graft-Versus-Host Disease (GVHD): Phase II Pilot Study.1786 Bennett, Charles Identification of Serious and Potentially Fatal Adverse Drug Reactions: Lessons Learned
from Identification of Rare, but Serious Adverse Events, for Five Common Pharmaceutical Agents Whose Toxicities Have Hematologic Implications.754 Berdeja, Jesus Stem Cell Mobilization with G-CSF Following
Standard ESHAP Chemotherapy in Patients with Lymphoma.2553 Bertolini, Francesco Continuous Infusion Endostatin Abrogates High-Grade Lymphoma Growth In Vivo,
Possibly by Inhibition of Clonogenic Endothelial Progenitors.2853 Bitran, Jacob High Dose Myeloablative Therapy and
Autologous Hematopoietic Stem Cell Support (ABMT) in Elderly (Older Than 65 Years) Patients with Relapsed Large Cell Lymphoma (LCC).1448 Blayney, Douglas Dose-Intense CHOPx2 Therapy of Intermediate Grade Lymphoma -- A Phase II
Study of the Southwest Oncology Group (SWOG).2862 Blum, William Primary Amyloidosis (AL) Patients with
Significant Organ Dysfunction Treated with Conventional Chemotherapy Followed by Single-Dose Total Body Irradiation (TBI) and Autologous Peripheral Blood Stem Cell Transplant (PBSC) Then IFN-alpha Maintenance: Tolerance and Efficacy.2663 Bogner, Christian Proliferating B-CLL Cells Are Highly
Susceptible to Inhibition of the Proteasome by Lactacystin.743 Bojko, Peter Comparison of G-CSF and GM-CSF in
Combination with Chemotherapy for Peripheral Blood Stem Cell (PBSC) Mobilization.756 Bolwell, Brian Etoposide (VP-16) + G-CSF Mobilizes
Different Dendritic Cell Subsets Than Does GCSF Alone.807 Bolwell, Brian Etoposide Contributes to Worse Mucositis
Following Autologous Transplantation.845 Bolwell, Brian The Presence of a Caregiver Is a Powerful
Prognostic Variable of Survival Following Allogeneic Bone Marrow Transplantation.1441 Borchmann, P. Phase-II Study of BBR 2778, a New Aza-
Anthracenedione, in Patients with Relapsed Aggressive Non-Hodgkin Lymphomas.2816 Bornhaeuser, Martin Highly Purified CD34 Positive Peripheral Blood Stem Cells for Allografting of Adult Patients
from Unrelated Donors: T Cell Add-Back Does Not Decrease the Risk of Infection and Relapse.635 Bosanquet, Andrew Bax Expression Correlates with Cellular Drug
Sensitivity to Doxorubicin, Cyclophosphamide and Chlorambucil but Not Fludarabine, Cladribine or Corticosteroids in B Cell Chronic Lymphocytic Leukemia.2655 Bosch, F. Fludarabine with Cyclophosphamide and Mitoxantrone (FCM) in Resistant or Relapsed Chronic Lymphocytic Leukemia (CLL): Final
Results of a Phase II Study.2764 Bracho, Francisco Despite Similar Morphology and
Immunophenotypic Characteristics, italicEx- Vivo/italic Expanded Dendritic Cells (DC) Derived from Cord Blood (CB) vs. Mobilized Adult Peripheral Blood (APB) Plastic Adherent Mononuclear Cells Are Significantly Deficient in Stimulating Allogeneic T-Cells.238 Brummendorf, Tim Telomere Length in Peripheral Blood Cells is Not Affected by Frequent Whole Blood and
Apheresis Platelet Donations.2592 Brummendorf, Tim Telomere Length in Peripheral Blood
Granulocytes Correlates with Response to Treatment with STI571.1794 Buckstein, Rena Variable Patterns of CNS
Prophylaxis in NHL: A Community Survey of Ontario Hematologists/Oncologists.2846 Buckstein, Rena Autologous Stem Cell Transplants Combined with Rituximab for Relapsed Follicular
Lymphoma Achieve Prolonged Clinical and Molecular Remissions.1731 Burt, Richard Supplementing Allogeneic Bone Marrow with
CD34 Enriched Peripheral Blood Cells.2654 Byrd, John Cladribine Has Clinical Activity in Patients with Fludarabine Refractory Chronic Lymphocytic
Leukemia Who Lack Pre-Treatment Cytopenias: Results from CALGB Study 9211.2834 Caballero, M.D. High Dose Therapy in Large Cell Lymphoma:
Analysis of Prognostic Factors in 452 Patients from the Gel-Tamo Spanish Registry.2522 Cabrera, J. Tumor-Specific Idiotype Vaccines in the
Treatment of Low Grade B-Cell Lymphoma.1810 Caggiano, Vincent First and All Cycle Febrile Neutropenia
Hospitalizations (FNH) and Costs in Intermediate Grade Non-Hodgkins Lymphoma (IGL) Patients on Standard-Dose CHOP Therapy.1680 Cahn, Jean-Yves Chronic Renal Failure: An Underestimated
Complication of Allogeneic Bone Marrow Transplantation.775 Carrum, George Submyeloablative Conditioning Regimens Using Anti-Lymphocyte Antibodies for
Allogeneic Stem Cell Transplantation.786 Casper, Jochen Toxicity Reduced Conditioning with Treosulfan and Fludarabine.
805 Cella, David Evaluation of Pain Associated with Oral
Mucositis (OM) Using an 11-Point Likert Scale by Patients Receiving Myeloablative Chemotherapy.style='font-size: 10.0pt;1421 Cerhan, James Association of Aspirin and Other Non-Steroidal
Anti-Inflammatory Drug Use with Incidence of Non-Hodgkin Lymphoma in a Cohort of Older Women.1649 Chakrabarti, Suparno Community Respiratory Virus and Adenovirus
Infections in Nonmyeloablative Transplant Recipients Conditioned with Campath-1H: High Incidence but Low Mortality.1612 Chan, Geoffrey Decreased Acute and Chronic Graft Versus
Host Disease with Early Full Donor Engraftment Following a Pentostatin-Based Preparative Regimen for Allogeneic Bone Marrow Transplant in High-Risk Patients.1692 Chang, Chung-Che High Tumor Load in Patients with Follicular
Lymphoma (FL) Post Allogeneic Bone Marrow Transplantation (Allo-BMT) Correlates with Relapse of Disease.766 Chang, Jason Increased Survival of Cyropreserved
Hematopoietic Cells by Overexpression of Manganese Superoxide Dismutase (MnSOD) Which Decreases Production of Reactive Oxygen Species (ROS) during Thawing.1739 Clark, Luciana Allogeneic Peripheral Blood Stem Cells vs.
Bone Marrow Transplantation for the Therapy of Hematological Malignancies: A Meta- Analysis of Randomized Controlled Trials.2530 Coiffier, Bertrand Phase II Study of PEG-Intron in Combination
with Chemotherapy for the Treatment of First Line Patients with Follicular Lymphoma Who Need To Be Treated. A GELA Study.628 Colomer, Dolors Drug-Induced Apoptosis Is Mediated by Bax
Conformational Changes in B-Cell Chronic Lymphocytic Leukemia.1507 Colovic, Milica Clinical Significance of Membrane Antigen
CD23 Positivity in B Chronic Lymphocytic Leukemia.1732 Cooney, Julian Allogeneic Transplantation in Hodgkin Disease
for Patients Who Fail Autologous Transplantation Is Safe and Effective.2180 Cooper, Nichola Rituxan Treatment in Patients with Immune Thrombocytopenic Purpura (ITP).
2836 Copelan, Edward Delay of Transplantation Beyond First Relapse of Low Grade NHL Adversely Influences Outcome .
1720 Corradini, Paolo Reduced Intensity Conditioning Followed by
Allografting of Hematopoietic Cells Can Produce Clinical and Molecular Remissions in Leukemias and Lymphomas.2849 Corradini, Paolo Long-Term Molecular Follow-Up in Indolent Lymphoma Patients Treated with High-Dose
Sequential Chemotherapy and Autografting: Durable Molecular and Clinical Remiussion Can Be Achieved Only in Follicular Subtypes.1740 Corsetti, Maria Teresa Allografting with Fludarabine-Based
Immunosuppressive Conditioning Regimens.1438 Cortelazzo, Sergio Prognostic
Scoring System for Primary Cutaneous B-Cell Lymphoma (PCBCL).1697 Couriel, Daniel Graft-Versus-Host Disease (GVHD) after Non-
Myeloablative (NMA) Versus Myeloablative (MA) Conditioning Regimens in Fully Matched Sibling Donor Hematopoietic Stem Cell Transplants (HSCT): An Update.1542 Coutre, Steven Efficacy and Safety of Alemtuzumab
(Campath-1H) Used on a Compassionate Basis in Refractory T-PLL.2518 Czuczman, Myron Phase II Study of Rituximab Plus Fludarabine
in Patients (pts) with Low-Grade Lymphoma (LGL): Final Report.2519 Czuczman, Myron Progression Free Survival (PFS) after Six
Years (Median) Follow-Up of the First Clinical Trial of Rituximab/CHOP Chemoimmunotherapy.1452 Dan, Kazuo Long-Term Follow-Up in Aggressive Non-
Hodgkin[ssquote]s Lymphoma (NHL) Patients Treated with rHuG-CSF(Lenograstim) Combined Biweekly CHOP Chemotherapy.548 Dang, Nam Phase II Study of Pentostatin for Relapsed T Cell Lymphomas: Efficacy and Effect on CD26+ T Cells.style='font-size: 10.0pt;
1464 Dann, Eldad High-Dose Cyclophosphamide (Ctx) in CHOP
Regimen Is Safe and Efficacious for Agrressive Non-Hodgkin Lymphoma.2707 Davis, Thomas Endothelial Cell Derived Growth Factor
(EDGF) Administration Supports Expansion and Mobilization of Hematopoietic Progenitor Cells and Increases Splenic Dendritic Cell Numbers.style='font-size: 10.0pt;765 de Boer, Fransien CD34 Subpopulation Marker Analysis
Combined with Early Apoptosis Assessment Reveals That L-Selectin May Be an Important Determinant of Platelet Engraftment after1500 Del Poeta, Giovanni Clinical Significance
of Soluble p53 in Bchronic Lymphocytic Leukemia.751 Demirer, Taner Mobilization of Peripheral Blood Stem Cells
with Chemotherapy and Recombinant Human Granulocyte-Colony Stimulating Factor (Rh- GSCF): A Randomized Evaluation of Different Doses of Rh-G-CSF.625 Desplat, Vanessa Overproduction of BCR-ABL Induces
Apoptosis in STI571-Resistant BaF/BCR-ABL Cell Lines.1439 Devin M. Burkitt Lymphoma (BL). A Prospective
Multicenter Study of 72 Adults Treated with the LMB Pediatric Protocol.1749 Dey, Bimalangshu Impact of Prophylactic Donor Leukocyte
Infusions on Mixed Chimerism, Graft-Vs-Host Disease (GvHD) and Anti-Tumor Response in Patients with Advanced Hematologic Malignancies Treated with Nonmyeloablative Conditioning and Allogeneic Stem Cell Transplantation (SCT).1753 Dey, Bimalangshu Achievement of Sustained Remissions
Despite Loss of Donor Chimerism (DC) in Patients with Chemotherapy-Refractory Non- Hodgkin[ssquote]s Lymphoma (NHL) Treated with Nonmyeloablative Conditioning and Allogeneic Stem Cell Transplantation (SCT).1453 Di Renzo, Mitoxantrone, Ifosfamide, Procarbazine and
Prednisone (MIPP Regimen) for Treatment of Refractory/Relapsed Non-Hodgkin Lymphomas (NHL). A Single Centre Experience.1547 Dimopoulos, M. Primary Treatment of Waldenstrom[ssquote]s Macroglobulinemia with Rituximab.
1803 Doorduyn, Jeanette Quality of Life (QOL) in Elderly Patients with Aggressive Non-Hodgkin[ssquote]s Lymphoma (NHL) Treated with CHOP.
2802 Drobyski, William Superior Survival Associated with
Transplantation of Matched Unrelated Versus One Antigen-Mismatched Unrelated or Highly HLA-Disparate Haploidentical Family Donor Marrow Grafts for the Treatment of Hematological Malignancies.1432 Dumontet, Charles Antioxidant Status in Patients with Aggressive Non Hodgkin[ssquote]s Lymphoma.
2128 Dupont, Jakob Primary Tumor Cells Expressing Human
Telomerase Reverse Transcriptase (hTERT) Are Killed by Specific Human Cytotoxic T Lymphocytes Generated Using Artificial Antigen Presenting Cells.688 Durie, Brian Low Dose Thalidomide Alone and in
Combination: Long Term Follow-Up.2544 Eilender, David Concurrent Fludarabine and Total Body
Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkins Lymphoma (NHL): A Phase I Trial.533 Ekstein, Dana Polymerase Chain Reaction (PCR)
Examination of CSF Cells Enhanses the Diagnosis of CNS Involvement by Lymphoma: A Retrospective Analysis of 111 CSF Studies .2845 El-rayes, Basil Long Term Comparison of Event Free and
Overall Survival in Patients with Non- Hodgkins Lymphoma (NHL) Treated with Autologous or Allogeneic Marrow/Stem Cell Transplantation on a Single Protocol over a 12 Year Period.522 Elstrom, Rebecca Utility of 18-FDG-PET Scanning in Lymphoma by WHO Classification.
1537 Faderl, Stefan An Exploratory Study of the Combination of
Monoclonal Antibodies CAMPATH-1H and Rituximab in the Treatment of CD52- and CD20- Positive Chronic Lymphoid Disorders.2493 Faderl, Stefan Phase I Study of Tezacitabine (FMdC) in Patients with Relapsed and Refractory
Hematologic Malignancies.1419 Fayad, Luis Primary Mediastinal Large B-Cell Lymphoma
(PMLBL): Poor Prognosis in Patients with Extranodal Sites.1541 Ferrajoli, Alessandra Campath-1H in Refractory Hematological
Malignancies Expressing CD-52. A Phase II Clinical Trial of 68 Patients2649 Flinn, Ian Fludarabine and Cyclophosphamide Achieves High Complete Response Rate in Patients
with Previously Untreated Chronic Lymphocytic Leukemia: ECOG 1997.2832 Flinn, Ian Rituximab during Autologous Stem Cell
Transplantion for Lymphoma Produces Lymphoma Free Grafts in Most Patients by PCR and Clonogenic Assays.1755 Flowers, C. Allogeneic Hematopoietic Stem Cell
Transplantation with Nonmyeloablative Conditioning for Patients with Chronic Lymphocytic Leukemia.1714 Forrest, Donna High-Dose Therapy and Allogeneic
Hematopoietic Stem Cell Transplantation for Progressive Follicular Lymphoma.2650 Garcia Manero,Guillermo Update of Results of the Combination of
Fludarabine, Cyclophosphamide and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL).567 Giraldo, Pilar Molecular Response to Anti Cd20 (Rituximab)
Therapy in Relapsed Follicular Lymphoma.2810 Girgis, Mark Low-Dose (550 cGy), Single Exposure Total
Body Irradiation (TBI) and Cyclophosphamide as Conditioning for Unrelated Donor (URD) Bone Marrow Transplantation (BMT) Results in Reduced Non-Relapse Mortality (NRM) in Comparison to Standard TBI-Based Regimens.627 Gocke, Christopher Bcl-2 Expression in Waldenstroms Macroglobulinemia.
1754 Goldstein, Steven A Prospective, Comparative Trial of High Dose
Therapy Followed by Allogeneic Versus Autologous Stem Cell Transplantation in 100 Patients with High Risk Lymphoma.2115 Gotlieb, Vladimir Diffuse Large Cells Lymphoma(DLCL) of the
Liver Treated with Highly Active Antiretroviral Therapy (HAART).557 Grefer, Jan B-Cell Depletion and Recovery after Treatment with the Anti-CD20 Monoclonal Antibody
Rituximab in Patients with Posttransplant Lymphoproliferative Disorders (PT-LPD).2534 Gregory, Stephanie Safety and Efficacy of Fludarabine and
Mitoxantrone with Rituximab Consolidation in Untreated Advanced Low Grade Non- Hodgkins Lymphoma (LG-NHL).2535 Gregory, Stephanie Bexxar[tm] Is a Well-Tolerated Therapy in Elderly Patients with Low-Grade or
Transformed Low-Grade Non- Hodgkins Lymphoma (NHL).1528 Greil, Richard Detection, Modification and Regulation of CD-
20 Antigen Expression during In Vitro and In Vivo Treatment with Rituximab (Rituxan) in CLL Patients.1529 Gupta, Niraj Re-Treatment with a Rituximab Based
Therapy Is Highly Effective in Autoimmune Hemolytic Anemia (AIHA) Associated with Chronic Lymphocytic Leukemia (CLL). Sunday Hall C 10:00 AM 6:00 PM style='font-size: 10.0pt;1530 Hainsworth, John Rituximab as First-Line and Maintenance
Therapy for Patients with Small Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL).2560 Hajjar, George Interim Results of a Phase I/II
Radioimmunotherapy Trial in Relapsed/Refractory Non-Hodgkins Lymphoma (NHL) Patients Given 90 Y-Labeled Anti-CD22 Humanized Monoclonal Antibody, Epratuzumab.853 Hamza, Nashaat Infectious Complications after Unrelated HLAMismatched Allogeneic Umbilical Cord Blood
Transplantation (UCBT) in Adults.2549 Hariharan, Kandasamy Therapeutic Activity of IDEC-114 (Anti-CD80) and Rituximab (Rituxan[reg]) in B-Cell Lymphoma.
2803 Hasegawa, Wanda Influence of One Human Leukocyte Antigen
Mismatch on Outcome of Allogeneic Bone Marrow Transplantation from Related Donors.1508 Hermann, Sandra Mutation of p53 in B-CLL: Relation to Prior
Alkylating Chemotherapy, Disease Prognosis and Impact on Distinct Drug Sensitivity Profiles.1410 Hernandez, Jesus CCND3 Rearrangements in Splenic Marginal
Zone Lymphomas.1423 Hernandez-Ilizaliturri,Francisco The Effects of Methylprednisolone (MP) on the Biological Anti-Tumor Activity of Rituximab on Non-Hodgkin Lymphoma (NHL) Cell Lines.
2521 Herold, Michael Efficacy and Toxicity of Rituximab Plus
Mitoxantrone, Chlorambucil, Prednisolone (MCP) Versus MCP Alone in Advanced Indolent NHL - Interim Results of a Clinical Phase III Study of the East German Study Group Hematology/Oncology (OSHO).787 Ho, Aloysius Reduced-Intensity Rituximab-Beam-Campath Allogeneic Transplantation for Indolent Non-
Hodgkin[ssquote]s Lymphoma.823 Holman, Peter A Phase I/II Study of High Dose Topotecan (T)
with Melphalan (M) Followed by Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) and Non-Hodgkins Lymphoma (NHL).2556 Honeychurch, Jamie Cyclophosphamide Increases Antibody-
Dependent Cytotoxicity and Improves Immunotherapy in a B-Cell Lymphoma Model.2561 Honeychurch, Jamie Treatment of B-Cell Lymphoma with Irradiation
and Anti-CD40 Induces a Potent CD8 T-Cell Response and Provides Long-Term Tumour Immunity.1696 Hou, Jeannie Potent Graft-Versus-Lymphoma Effect after
Non-Myeloablative Stem Cell Transplant in Refractory Non-Hodgkins Lymphoma: Role of Rapid Complete Donor Chimerism.1504 Hsi, Eric Prognostic Significance of CD38 and CD20
Expression in Chronic Lymphocytic Leukemia (CLL) as Assessed by Quantitative Flow Cytometry.558 Iannitto, Emilio Pentostatin in the Treatment of Splenic
Lymphoma with Villous Lymphocytes. A Phase II Study. Preliminary Results.712 Iannone, Robert A Comparison of Intravenous Busulfan and
Total Body Irradiation in Nonmyeloablative Conditioning for BMT.1413 Ichimura, Koichi Blastic NK Cell Lymphoma: A Clinicopathological Study of Japanese 16 Cases.
1620 Iuchi, Yasuyuki Dendritic Cells Pulsed with Heat Shock
Proteins Derived from Leukemia Cells Are Effective in Immunotherapy of Mice after Syngeneic Bone Marrow Transplantation.1454 Jaccard, Arnaud Impact of 18-FDG PET in the Management of
Patients with Hodgkins Disease or High-Grade Non-Hodgkins Lymphoma: A Prospective Study.1676 Jacobsohn, David Pentostatin: A Promising Treatment for
Refractory Chronic GVHD.657 Jacobson, Joth Beta 2 Microglobulin (B2M) and Albumin
Define a New Staging System for Multiple Myeloma: The Southwest Oncology Group Experience.2505 Janik, John Serum Soluble IL-2 Receptor Levels Are
Elevated in Patients with Anaplastic Large Cell Lymphoma (ALCL).529 Jenner, Michael A Universal Strategy for Quantifying BCL-
2/IgH Breakpoints in Follicular Lymphoma.423 Johnston, James The Activity of TRAIL Alone and in
Combination with F-ara-A or CLB in CLL.1401 Jones, Margaret The Differential Expression of Proteins in
Diffuse Large B Cell Lymphoma.1263 Josting, A. Erythropoietin Decreases Transfusion
Requirements in Patients with Relapsed Lymphoma Treated with the Cologne High- Dose Sequential Chemotherapy Regimen Prior to Autologous Stem Cell Support.2848 Josting, A. Cologne High-Dose Sequential Chemotherapy
in Relapsed and Refractory Hodgkin's and Aggressive Non-Hodgkin's Lymphoma - Results of a Multicenter Phase-II Study.2514 Jundt, Franziska Activated Notch1 Signaling Promotes Tumor
Cell Proliferation and Survival in Hodgkin and Anaplastic Large Cell Lymphoma.1433 Kaminski, Mark Acute and Delayed Hematologic Toxicities Associated with Bexxar[tm] Therapy Are
Modest: Overall Experience in Patients with Low-Grade and Transformed Low-Grade NHL.1790 Kaminski, Mark Treatment of Transformed and Refractory Low-
Grade Lymphoma with Bexxar[tm] Therapy Is Associated with Improvements in Quality of Life.2526 Kaminski, Mark Tolerance of Treatment Subsequent to
Frontline Bexxar[tm] (Tositumomab and Iodine I 131 Tositumomab) in Patients (Pts) with Follicular Lymphoma.2651 Keating, Michael Infectious Complications in Fludarabine
Refractory CLL Patients.1544 Kennedy, B. Eradication of Detectable Minimal Disease
with Campath-1H Therapy Results in Prolonged Survival in Patients with Refractory B-CLL.1459 Kewalramani, Tarun Rituximab Significantly Increases the
Complete Response Rate in Patients with Relapsed or Primary Refractory DLBCL Receiving ICE as Second-Line Therapy (SLT).795 Khouri, Issa Long Term Remission and Low Mortality
Achieved with Cisplatin, Fludarabine, Cytarabine Nonablative Preparative Regimen and Allogeneic Stem Transplantation (AST) for Histologically Aggressive Non-Hodgkins Lymphoma (NHL).1745 Khouri, Issa Allogeneic Transplantation for Poor Risk
Mantle Cell Lymphoma (MCL): Chemosensitivity Predicts Superior Outcome.1746 Khouri, Issa Nonablative Allogeneic Stem Cell
Transplantation (AST) for Non- Hodgkins Lymphoma (NHL): Improved Outcome with Low Incidence of Acute GVHD and Treatment Related Mortality.568 Kirchner, Hartmut Chemoimmunotherapy with Fludarabine,
Bendamustine and Rituximab for Relapsed Low Grade Malignant Non-Hodgkins Lymphoma.2543 Koenigsmann, Michael Bendamustin in Combination with Fludarabin
for the Treatment of Refractory or Relapsed Low-Grade Lymphoma - A Multicenter Phase I/II Trial of the East German Study Group for Hematology and Oncology (OSHO).1396 Kok, Marleen CD27 Is an Independent Prognostic Factor
for Outcome in Indolent Non-Hodgkins Lymphoma.569 Krmer, Alwin Treatment of Patients with Relapsed or
Refractory Aggressive Non-Hodgkins Lymphoma with a Combination of a Taxane, Cyclophosphamide and Rituximab.1737 Kyriakou, C. Outcome of Non-Myeloablative Stem Cell
Transplantation for NHL Is Dependent on Histology: Good for Patients with Low Grade Disease and Poor for Those with High Grade Lymphoma.2531 Lopez, A. Final Results of a Phase II Study To Evaluate the Efficacy and Safety of Treatment and Retreatment with Rituximab in Relapsed Follicular or Low-Grade NHL.
525 Lee, Woo Prediction of Clinical Relapse by Quantitative Real-Time Polymerase Chain Reaction(Q-Rt-
PCR) of the t(14;18) Carrying Cells in Patients with Follicular Lymphoma(FL).2503 Lei, Kenny Diagnostic and Prognostic Implications of
Circulating Cell-Free Epstein-Barr Virus DNA in Natural Killer/T-Cell Lymphoma.1443 Leitch, Heather Limited Stage Mantle Cell Lymphoma: Clinical
Outcome in Patients from British Columbia.559 Leonard, John Interim Safety and Efficacy Results of
Bexxar in a Large Multicenter Expanded Access Study.2527 Leonard, John Bexxar[tm] (Tositumomab and Iodine I 131
Tositumomab) Results in Durable Long-Term Responses in Patients with Poor Prognosis, Multiple Relapsed (Rel), and Refractory (Ref) Low-Grade or Transformed Low-Grade Non- Hodgkins Lymphoma (NHL).1707 Levine, John Allogeneic Transplants Are Associated with
Fewer Relapses but Higher Treatment Related Mortality Than Autologous Transplants for Lymphoblastic Lymphoma.2661 Levy, V. Advanced Waldenstrom Macroglobulinemia :
Usefulness of the Morel's Scoring System in Establishing Prognosis.2524 Linden, Ola Durable Response to 90-Yttrium-Epratuzumab (hLL2) in B-Cell Lymphoma Failing
Chemotherapy by Using Dose-Fractionation Schedule2540 Link, Brian A Phase II Study of Remitogen[tm] (Hu1D10), a Humanized Monoclonal Antibody in Patients with Relapsed or Refractory Follicular, Small
Lymphocytic, or Marginal Zone/MALT B-Cell Lymphoma.2550 Link, Brian Phase I Study To Assess Safety and Activity
of Oligodeoxynucleotide CpG 7909 (Promune[tm]) in Patients with Previously Treated Non-Hodgkins Lymphoma.1403 Lossos, Izidore Analysis of FAS (CD95) Gene Mutations in
Higher-Grade Transformation of Follicle Center Lymphoma (FCL).2541 Lucie, Norman Phase II Study of Fludarabine and
Cyclophosphamide in the Treatment of Relapsed Low Grade Non-Hodgkins Lymphoma.546 Mangel, J. Upfront HDMVP Chemotherapy without
Radiation for the Treatment of Newly Diagnosed Primary CNS Lymphoma.2833 Mangel, J. Complete Clinical and Molecular Remissions Can Be Achieved Following Autologous Stem
Cell Transplantation in Combination with Rituximab Immunotherapy for the Treatment of Newly Diagnosed Mantle Cell Lymphoma.570 Martin, Simona Clearing of Risidual Disease in Patients with
Follicular Lymphoma Depends on the Type of Chemotherapy Combined with the Anti-CD20 Monoclonal Antibody (Rituximab) and the Time Point of Therapy.1762 Martino, Rodrigo Low Transplant-Related Mortality after Second Allogeneic Peripheral Blood Stem Cell
Transplantation with Reduced-Intensity Conditioning in Adult Patients Who Failed a Prior Autologous Transplant.1418 Micallef, Ivana International Prognostic Index (IPI) Predicts Outcome after Histological Transformation of
Low Grade Non-Hodgkin Lymphoma.2842 Moskowitz, Craig Phase II Study of Accelerated Fractionation Involved Field Radiotherapy (IFRT), Total
Body Irradiation (TBI), Ifosfamide and Continuous Infusion Etoposide with Autologous Stem Cell Transplantation (ASCT) in the Treatment of Patients with Relapsed and Primary Refractory Aggressive Non- Hodgkins Lymphoma (NHL).1536 Nabhan, Chadi Phase I Study of Rituximab and Campath-1H
in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.527 Naumann, Ralph Positron Emission Tomography with 18F-FDG
in the Evaluation of Post-Treatment Residual Mass in Patients with Malignant Lymphoma.571 Nikkuni, Koji A Phase II Multicenter Clinical Trial of High- Dose Bi-Weekly THP-COP with G-CSF
Support (HDBW-TCOP(G)) for Non- Hodgkins Lymphoma.1444 Pangalis, G.A. Intensified CNOP Versus CHOP in the
Treatment of Aggressive Non- Hodgkins Lymphomas: A Randomized Trial of the Hellenic Cooperative Lymphoma Group.838 Platzbecker, Uwe Double Lumen Port Access in Patients
Receiving Allogeneic Blood Stem Cell Transplantation - An Alternative to Hickman Catheters?1532 Polliack, Aaron Fludarabine (FLU)-Containing Regimen and
Rituximab (RI) as Primary Therapy with Curative Intent for Younger Patients with Progressive and Advanced B- CLL: High Rate of Initial Response Including Molecular Remissions.1411 Porcu, Pierluigi MUM-1 and BCL-6 Expression Identifies
Distinct Prognostic Subgroups of Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Bone .1538 Rai, Kanti Efficacy and Safety of Alemtuzumab
(Campath-1H) in Refractory B-CLL Patients Treated on a Compassionate Basis.2528 Rambaldi,Alessandro Monitoring of Minimal Residual Disease after
CHOP and Rituximab in Previously Untreated Follicular Lymphoma Patients.836 Ratanatharathorn, Voravit Hematopoietic Stem Cell Transplantation
(HSCT) in Lymphoma Patients Receiving Prior Therapy with Tositumomab and Iodine I131 Tositumomab(Bexxar).2414 Rees, K. Genetic Events Associated with
Transformation of Non-Hodgkins Lymphoma .1446 Ribera, J. Intensive Chemotherapy for Burkitts
Lymphoma and Leukemia: Similar Results for HIV Positive and Negative Adult Patients Treated with PETHEMA ALL3/97 Protocol.1764 Rizzieri, David Non-Myeloablative Allogeneic Transplantation
Using T Depleted Matched Sibling Peripheral Blood Stem Cells.2805 Rizzieri, David Non-Myeloablative Transplantation Using CAMPATH 1H for T Depletion of Mismatched,
Related Donor Peripheral Blood Stem Cells.2851 Rizzieri, David Dose Dense, High Intensity Therapy for Mantle
Cell Lymphoma.2844 Rodriguez, Results of High Dose Chemotherapy and
Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma (PTCL). The Spanish Lymphoma Cooperative Group Experience (GEL/TAMO).2532 Rohatgi, Nitin Sequential Therapy with Fludarabine Followed by Cyclophosphamide, Mitoxantrone,
Vincristine and Prednisone (CNOP) for Low- Grade Follicular Lymphomas: Results of a Phase II Trial.2890 Rowley, Scott Autologous Hematopoietic Stem Cell (HSC)
Transplantation of Patients 65 Years of Age or Older.1457 Sarris, Andreas Non-Hodgkins Lymphoma Involving
the Testis: Results of Treatment with CHOP, Intrathecal Methotrexate and Scrotal Radiotherapy.553 Schmidt, Burkhard Radioimmunotherapy (RAIT) with 131-Iodine
Labeled Rituximab in Patients with B Cell NHL in a Myeloablative and Non-Myeloablative Regimen.2841 Seyfarth, Baerbel Mantle Cell Lymphoma: Promising Results
with Upfront Stem Cell Transplantation Using the Rituximab/TBI/CY High-Dose Regimen.1426 Simonitsch-Klupp,Ingrid The Plasmablastic Variant of Diffuse Large BCell
Lymphoma Is Associated with Poor Clinical Outcome.538 Soubeyran, Pierre Circulating t(14;18)-Bearing Cell Amount May
Be a Valid Target To Improve Response Evaluation in Follicular Lymphoma.2813 Spitzer, Thomas Durable Progression Free Survival (PFS)
Following Non-Myeloablative Bone Marrow Transplantation (BMT) for Chemorefractory Diffuse Large B Cell Lymphoma (B-LCL).826 Stiff, Patrick TBI-Based Autologous Stem Cell Transplants
Can Safely Be Performed on an Outpatient Basis.554 Talpur, Rakhshandra Bexarotene Monotherapy and Combination
Therapy for Cutaneous T-Cell Lymphoma.547 Thieblemont,Catherine Splenectomy Is an Effective Treatment in
Splenic Margnial Zone B-Cell Lymphomas.1440 Timmerman, John A Phase 2 Study Demonstrating Recombinant Idiotype Vaccine Elicits Specific Anti-Idiotype Immune Responses in Aggressive Non-
Hodgkins Lymphoma.564 Tomita, Naoto Prophylactic Intrathecal Methotrexate Reduces Central Nervous System Relapse and
Improves Long-Term Survival in Aggressive Non-Hodgkins Lymphoma.1427 Tompkins, Kirsty Neutropenic Events in Patients Receiving
CHOP Chemotherapy for Large Cell Non- Hodgkins Lymphoma:Predicting Who Is at Risk.1393 Torlakovic, Emina Expression of the B-Cell Transcription Factor PU.1 Is Strongly Correlated with CD10,
CD79a, CD20, CD22, and bcl-6 Expression in Diffuse Large B-Cell Lymphoma (DLBCL).2537 Trneny, Marek Anti CD20 Antibody (Rituximab) Therapy
Leads to High Molecular Remission Rate with Favourable Outcome in Patients with Non- Hodgkins Lymphoma.1460 Tsurumi, Hisashi Biweekly CHOP / Biweekly THP-COP
Regimen in the Treatment of Aggressive Non- Hodgkins Lymphoma - Comparison of Doxorubicin and Pirarubicin : A Randomized Phase II Study.1461 Tulpule, Anil Liposomal Doxorubicin (TLC-D99) in
Combination with Cyclophosphamide (C), Vincristine (V), and Prednisone (P) Is Active in Newly Diagnosed Aggressive Non- Hodgkins Lymphoma (NHL).1694 Tzolas, A. Non-Myeloablative and Myeloablative Peripheral Blood Stem Cell Transplantation:
Comparison of Post-Transplant Complications and Survival.788 van Besien, Koen Fludarabine-Melphalan Is Equivalent to
Fludarabine-Thiotepa-TBI-Based Conditioning for Allogeneic Transplantation in Advanced Hematologic Malignancies. Experience in 61 Consecutive Patients.2653 Weiss, Mark Pentostatin and Cyclophosphamide: A New Active Regimen for Patients with Fludarabine
Refractory CLL.2529 Wilder, Diane Efficacy of Fludarabine, Mitoxantrone,
Dexamethasone Alternating with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (FMD/CHOP) in Bulky Follicular Non-Hodgkins Lymphoma1447 Wilson, Wyndham Rituximab May Overcome Bcl-2-Associated
Chemotherapy Resistance in Untreated Diffuse Large B-Cell Lymphomas.2539 Witzig, Thomas Zevalin Radioimmunotherapy Can Be
Safely Administered to Patients with Relapsed or Refractory, B Cell Non-Hodgkin[scquote]s Lymphoma (NHL).1456 Younes, Anas High Response Rate and Complete Remission
Rate Achieved by Adding Rituximab to Taxol Plus Topotecan (TTR) with G-CSF Support for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Lymphoma.2566 Younes, Anas Interleukin-12 (IL-12) Decreases Serum VEGF and b-FGF Levels and Induces Clinical
Remissions in Patients with Relapsed Non- Hodgkins Lymphoma (NHL).565 Zelenetz, Andrew Individualized Patient Dosing with
Radioimmunotherapy Prevents Under- and Over-Dosing of Patients and Is Associated with Tolerable and Predictable Hematologic Toxicity in Patients with Non-Hodgkins Lymphoma (NHL).